MCID: INT007
MIFTS: 58

Intermediate Coronary Syndrome

Categories: Cardiovascular diseases

Aliases & Classifications for Intermediate Coronary Syndrome

MalaCards integrated aliases for Intermediate Coronary Syndrome:

Name: Intermediate Coronary Syndrome 12 15 17
Unstable Angina 12 15 33
Angina, Unstable 44 72
Myocardial Preinfarction Syndrome 72
Anginal Chest Pain at Rest 12
Impending Infarction 12
Preinfarction Angina 12
Worsening Angina 12
Angina at Rest 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8805
ICD9CM 35 411.1
MeSH 44 D000789
NCIt 50 C66911
ICD10 33 I20.0
UMLS 72 C0002965 C0086666

Summaries for Intermediate Coronary Syndrome

MalaCards based summary : Intermediate Coronary Syndrome, also known as unstable angina, is related to heparin-induced thrombocytopenia and anterolateral myocardial infarction, and has symptoms including angina pectoris An important gene associated with Intermediate Coronary Syndrome is UBAP1 (Ubiquitin Associated Protein 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Selenium Micronutrient Network. The drugs Nicorandil and Udenafil have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Intermediate Coronary Syndrome

Diseases related to Intermediate Coronary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 heparin-induced thrombocytopenia 30.9 SERPINC1 F3
2 anterolateral myocardial infarction 30.7 PLAT ACE
3 pulmonary edema 30.6 PIK3C2A CRP ACE
4 coronary restenosis 30.5 SERPINC1 ACE
5 cardiac arrest 30.5 TNNT2 PIK3C2A ACE
6 cardiac rupture 30.5 PLAT CRP
7 carotid stenosis 30.5 SELP CRP ACE
8 heart valve disease 30.4 VWF CRP ACE
9 gas gangrene 30.4 TNNI3 PIK3C2A MB
10 atrial standstill 1 30.3 TNNT2 TNNI3 ACE
11 proteasome-associated autoinflammatory syndrome 1 30.3 SELP IL6 CRP
12 cardiogenic shock 30.1 PLAT PIK3C2A IL6
13 coronary thrombosis 30.1 VWF SERPINC1 PLAT P2RY12 F3
14 hypertrophic cardiomyopathy 30.0 TNNT2 TNNT1 TNNI3 ACE
15 thrombophilia 30.0 VWF SERPINC1 F3
16 essential thrombocythemia 30.0 VWF SELP ITGA2B F3
17 femoral neuropathy 29.9 PLG F3
18 systolic heart failure 29.7 IL6 CRP ACE
19 thrombophilia due to thrombin defect 29.6 VWF SERPINC1 PLAT F3
20 end stage renal failure 29.6 IL6 CRP ACE
21 pulmonary hypertension 29.6 VWF PLAT F3 ACE
22 ischemia 29.6 SELP PLAT MB ACE
23 inferior myocardial infarction 29.4 PLG PLAT PIK3C2A
24 thrombosis 29.2 VWF SERPINC1 SELP PLAT P2RY12 F3
25 peripheral artery disease 29.0 SELP P2RY12 IL6 CRP ACE
26 arteriosclerosis 29.0 SELP IL6 F3 CRP ACE
27 thrombocytosis 29.0 SERPINC1 SELP IL6 F3 CRP
28 antiphospholipid syndrome 28.9 VWF SERPINC1 SELP PLAT F3
29 pulmonary embolism 28.8 VWF TNNT2 TNNI3 SERPINC1 PLAT F3
30 coronary heart disease 1 28.5 SELP PLAT IL6 CRP ACE
31 dilated cardiomyopathy 28.5 TNNT2 TNNT1 TNNI3 MB IL6 CRP
32 intermittent claudication 28.4 VWF SERPINC1 SELP IL6 CRP ACE
33 pre-eclampsia 28.3 VWF SERPINC1 SELP IL6 F3
34 angina pectoris 28.2 SERPINC1 PLAT PIK3C2A IL6 CRP ACE
35 endocarditis 28.1 TNNI3 SERPINC1 PLAT PIK3C2A IL6 CRP
36 coronary stenosis 28.0 VWF TNNI3 PIK3C2A IL6 CRP ACE
37 peripheral vascular disease 27.7 VWF SERPINC1 SELP PLAT IL6 F3
38 cerebrovascular disease 27.6 VWF SELP PLAT ITGA2B IL6 CRP
39 coronary artery anomaly 27.4 TNNT2 TNNI3 SELP PLG PLAT PIK3C2A
40 vascular disease 26.9 VWF SERPINC1 SELP PLG PLAT IL6
41 heart disease 26.4 VWF TNNT2 TNNI3 SERPINC1 SELP PLAT
42 acute myocardial infarction 25.3 VWF TNNT2 TNNI3 SERPINC1 SELP PLG
43 arteries, anomalies of 25.1 VWF TNNI3 SERPINC1 SELP PLG PLAT
44 myocardial infarction 22.8 VWF TNNT2 TNNT1 TNNI3 SERPINC1 SELP
45 familial isolated restrictive cardiomyopathy 10.7 TNNT2 TNNI3
46 aspirin allergy 10.5 SERPINC1 ITGA2B
47 chlamydia pneumonia 10.5
48 chlamydia 10.5
49 renal artery obstruction 10.5 SERPINC1 ACE
50 rheumatic myocarditis 10.5 TNNI3 CRP

Comorbidity relations with Intermediate Coronary Syndrome via Phenotypic Disease Network (PDN): (show top 50) (show all 101)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Stress Disorder
Allergic Urticaria Angina Pectoris
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Asbestosis Atrioventricular Block
Atrophic Gastritis Basilar Artery Insufficiency
Benign Essential Hypertension Benign Hypertensive Renal Disease
Bleeding Disorder, Platelet-Type, 11 Bronchitis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebrovascular Disease
Chronic Intestinal Vascular Insufficiency Constrictive Pericarditis
Coronary Artery Aneurysm Deficiency Anemia
Diabetic Polyneuropathy Diaphragm Disease
Dressler's Syndrome Duodenitis
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gallbladder Disease
Gastroesophageal Reflux Generalized Atherosclerosis
Gout Heart Disease
Hemopericardium Hyperlipoproteinemia, Type I
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hypertension, Essential Hypertensive Encephalopathy

Graphical network of the top 20 diseases related to Intermediate Coronary Syndrome:



Diseases related to Intermediate Coronary Syndrome

Symptoms & Phenotypes for Intermediate Coronary Syndrome

UMLS symptoms related to Intermediate Coronary Syndrome:


angina pectoris

MGI Mouse Phenotypes related to Intermediate Coronary Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 ACE CRP F3 IL6 ITGA2B MB
2 homeostasis/metabolism MP:0005376 10.17 ACE CRP F3 IL6 ITGA2B MB
3 hematopoietic system MP:0005397 10.15 ACE F3 IL6 ITGA2B MB P2RY12
4 immune system MP:0005387 10 ACE CRP F3 IL6 ITGA2B PIK3C2A
5 mortality/aging MP:0010768 9.93 ACE F3 IL6 MB PIK3C2A PLAT
6 muscle MP:0005369 9.5 F3 IL6 MB PLAT TNNI3 TNNT1
7 respiratory system MP:0005388 9.17 F3 IL6 MB PLAT PLG SELP

Drugs & Therapeutics for Intermediate Coronary Syndrome

Drugs for Intermediate Coronary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
2
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
9
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
10
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
11
Chromium Approved Phase 4 7440-47-3 27668
12
Fondaparinux Approved, Investigational Phase 4 104993-28-4
13
Citalopram Approved Phase 4 59729-33-8 2771
14
Fenofibrate Approved Phase 4 49562-28-9 3339
15
Ezetimibe Approved Phase 4 163222-33-1 150311
16
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
17
Digoxin Approved Phase 4 20830-75-5 30322 2724385
18
Simvastatin Approved Phase 4 79902-63-9 54454
19
Pravastatin Approved Phase 4 81093-37-0 54687
20
Cangrelor Approved Phase 4 163706-06-7 9854012
21
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
22
Desflurane Approved Phase 4 57041-67-5 42113
23
Ramipril Approved Phase 4 87333-19-5 5362129
24
Norepinephrine Approved Phase 4 51-41-2 439260
25
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
26
Racepinephrine Approved Phase 4 329-65-7 838
27
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
28
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
29
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
30
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
31
Amlodipine Approved Phase 4 88150-42-9 2162
32
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
33
Adenosine Approved, Investigational Phase 4 58-61-7 60961
34
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
35
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
36
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
37
Bisoprolol Approved Phase 4 66722-44-9 2405
38
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
39
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
40
Atorvastatin Approved Phase 4 134523-00-5 60823
41
Abciximab Approved Phase 4 143653-53-6
42
Metformin Approved Phase 4 657-24-9 4091 14219
43
Ticagrelor Approved Phase 4 274693-27-5 9871419
44
Dalteparin Approved Phase 4 9005-49-6
45
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
46
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
47
Montelukast Approved Phase 4 158966-92-8 5281040
48
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
49
Tenecteplase Approved Phase 4 191588-94-0
50
Candesartan cilexetil Approved Phase 4 145040-37-5 2540

Interventional clinical trials:

(show top 50) (show all 576)
# Name Status NCT ID Phase Drugs
1 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
2 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
3 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
4 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
5 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
6 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
7 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
8 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
9 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
10 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
11 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
12 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
13 Minimizing Post-Procedural Vascular Complications: Comparing Bivalirudin Versus Heparin/GP IIB/IIA in Patients Undergoing Percutaneous Coronary Intervention Unknown status NCT00476944 Phase 4
14 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
15 Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Lesion: A Optical Coherent Tomography Prospective, Multicenter Study Unknown status NCT01925027 Phase 4
16 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
17 A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris Completed NCT02007187 Phase 4 Danhong injection;Placebo
18 The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study Completed NCT02612116 Phase 4 Pulverized ticagrelor sublingually;Pulverized ticagrelor orally;Integral ticagrelor
19 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Naloxone or Morphine Alone - a Randomized Study Completed NCT02939248 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,naloxone
20 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Metoclopramide or Morphine Alone - a Randomized Study Completed NCT02939235 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,metoclopramide
21 Diagnosis and Treatment of Acute Coronary Syndrome in the Emergency Department- The Impact of Rapid Bedside cTnl on Outcome. Completed NCT00276432 Phase 4
22 Safety and Efficacy of Sustained-Release (SR) Bupropion for Smokers Hospitalized Smokers With Acute Coronary Heart Disease Completed NCT00181818 Phase 4 bupropion SR (sustained-release)
23 Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) Completed NCT00231738 Phase 4 Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
24 Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
25 Low Restenosis Rate of the NIR Coronary Stent: Results of the Danish Multicenter Stent Study (DANSTENT) – a Randomized Study Comparing a First-Generation With a Second-Generation Stent. Completed NCT00139802 Phase 4
26 A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS) Completed NCT00327418 Phase 4 Atorvastatin
27 Evaluation of the Effect of Atorvastatin and Pioglitazone in Carotid Atherosclerosis With the Use of 18Fluoride-Fludeoxyglucose(FDG) Positron Emission Tomography-computed Tomography (PET-CT)Imaging Completed NCT01341730 Phase 4 Atorvastatin 20mg;Atorvastatin 20 mg + Pioglitazone 30 mg
28 A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry. Completed NCT01895751 Phase 4
29 Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography Completed NCT00700037 Phase 4 high-dose atorvastatin;low-dose atorvastatin
30 Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease. Study With Angiography and OCT Follow-up. Completed NCT01637012 Phase 4
31 FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8) Completed NCT00790907 Phase 4 fondaparinux background and standard dose UFH;Fondaparinux background and low dose heparin;Open label fondaparinux
32 Exercise Training Improves Oscillatory Pattern and Arterial Baroreflex Control of Sympathetic Nerve Activity in Patients With Chronic Heart Failure Completed NCT02219451 Phase 4
33 Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT) Completed NCT00190580 Phase 4 valsartan;Conventional antihypertensive drugs
34 Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial Completed NCT00419471 Phase 4 Escitalopram;Placebo
35 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
36 Randomized Clinical Trial Comparing A Titanium-Nitride-Oxide Coated Stent With A Zotarolimus-Eluting Stent in Patients With Coronary Artery Disease Completed NCT00492908 Phase 4
37 A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin Completed NCT02984982 Phase 4 alirocumab SAR236553;atorvastatin;rosuvastatin;fenofibrate;bezafibrate;ezetimibe;antiplatelets;anticoagulants
38 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
39 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
40 Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent Completed NCT01826552 Phase 4
41 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4 aspirin;clopidogrel
42 A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study Completed NCT00986050 Phase 4 Abciximab
43 Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI) Completed NCT01293097 Phase 4 Atorvastatin;Statin
44 The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial Completed NCT02733341 Phase 4 Cangrelor;Ticagrelor
45 The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT) Completed NCT01331967 Phase 4 Pioglitazone
46 Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions Completed NCT00735280 Phase 4 unfractionated heparin
47 Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Prospective, Randomized, Controlled Study Completed NCT00295191 Phase 4
48 The Ischemia Management With Accupril Post Bypass Graft Via Inhibition of the coNverting Enzyme (IMAGINE) Trial Completed NCT00269243 Phase 4 Quinapril
49 Comparison of Digoxin and Ivabradine in Heart Failure With Preserved Systolic Function. Time to Rethink About Digoxin. Completed NCT01699776 Phase 4 Ivabradine;Digoxin
50 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2) Completed NCT00133003 Phase 4 Abciximab;Placebo

Search NIH Clinical Center for Intermediate Coronary Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :


abciximab
Alirocumab
bivalirudin
Dalteparin
Dalteparin Sodium
Enoxaparin
eptifibatide
Fondaparinux
heparin
Heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
lepirudin
Nadroparin
tirofiban
TIROFIBAN HYDROCHLORIDE
Verapamil

Cochrane evidence based reviews: angina, unstable

Genetic Tests for Intermediate Coronary Syndrome

Anatomical Context for Intermediate Coronary Syndrome

MalaCards organs/tissues related to Intermediate Coronary Syndrome:

41
Heart, Testes, Endothelial, Kidney, Lung, Monocytes, Neutrophil

Publications for Intermediate Coronary Syndrome

Articles related to Intermediate Coronary Syndrome:

(show top 50) (show all 12705)
# Title Authors PMID Year
1
Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting. 38
31432633 2020
2
Cannabis use and acute coronary syndrome. 38
30964363 2019
3
Epidemiology of acute coronary syndrome co-existent with allergic/hypersensitivity/anaphylactic reactions (Kounis syndrome) in the United States: A nationwide inpatient analysis. 38
31204069 2019
4
The prognostic value of various carotid ultrasound parameters in patients at high and very high cardiovascular risk. 38
31230934 2019
5
Real-world use of ticagrelor versus clopidogrel in percutaneous coronary intervention-treated ST-elevation myocardial infarction patients: A single-center registry study. 38
31296977 2019
6
Comparative trends in coronary heart disease subgroup hospitalisation rates in England and Australia. 38
30948515 2019
7
Incidence and outcomes of unstable angina compared with non-ST-elevation myocardial infarction. 38
31018955 2019
8
Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. 38
30898480 2019
9
Implementation of a Brazilian Cardioprotective Nutritional (BALANCE) Program for improvement on quality of diet and secondary prevention of cardiovascular events: A randomized, multicenter trial. 38
31349110 2019
10
"Unstable angina" in a man aged 53 years. 38
31154429 2019
11
Sympathectomy versus conventional treatment for refractory coronary artery spasm. 38
30896452 2019
12
The Evolving Management of Aortic Valve Disease: 5-Year Trends in SAVR, TAVR, and Medical Therapy. 38
31277791 2019
13
Association of 584C/T polymorphism in endothelial lipase gene with risk of coronary artery disease. 38
31020688 2019
14
Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. 38
30796567 2019
15
Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial Infarction and Coronary Heart Disease. 38
31424985 2019
16
Is inspiratory muscle training (IMT) an acceptable treatment option for people with chronic obstructive pulmonary disease (COPD) who have declined pulmonary rehabilitation (PR) and can IMT enhance PR uptake? A single-group prepost feasibility study in a home-based setting. 38
31399454 2019
17
Can Thrombus Burden Predict Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction? 38
30621429 2019
18
Early diagnostic value of circulating microRNAs in patients with suspected acute myocardial infarction. 38
30623425 2019
19
Predicting Major Adverse Events in Patients With Acute Myocardial Infarction. 38
31416527 2019
20
Interleukin-1 blockade treatment decreasing cardiovascular risk. 38
31415103 2019
21
Relationship between seasonal influenza rates and hospitalization and mortality rates due to acute cardiovascular diseases in a Spanish region. 38
30738617 2019
22
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER. 38
31390907 2019
23
Usefulness of the CHA2DS2-VASc Score to Predict Adverse Outcomes in Acute Coronary Syndrome Patients Without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. 38
31235063 2019
24
The effect of clinical coronary disease severity on outcomes of carotid endarterectomy with and without combined coronary bypass. 38
31401112 2019
25
In-Hospital Healthcare Utilization, Outcomes, and Costs in Pre-Hospital-Adjudicated Low-Risk Chest-Pain Patients. 38
31388939 2019
26
Contemporary differences between men and women with acute coronary syndromes: CIAM multicenter registry. 38
31260420 2019
27
PPARA, PPARD and PPARG gene polymorphisms in patients with unstable angina. 38
31252163 2019
28
Anti-Thrombotic Strategies in Elderly Patients Receiving Platelet Inhibitors. 38
31384933 2019
29
Incidence, Predictors, and Outcomes of Acute Ischemic Stroke Following Percutaneous Coronary Intervention. 38
31395220 2019
30
The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry. 38
30414798 2019
31
Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. 38
30941884 2019
32
Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. 38
31405751 2019
33
[Early Invasive Strategy in Patients over 75 Years with Acute Coronary Syndrome. A Single Center Study]. 38
31397226 2019
34
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. 38
31272931 2019
35
Resource Utilization and Costs Associated With Percutaneous Coronary Intervention When Treating Patients With Acute Coronary Syndrome in the Mexican National Institute of Cardiology "Ignacio Chávez". 38
31419609 2019
36
Pseudo-Wellens Syndrome in a Patient with Hypertension and Left Ventricular Hypertrophy. 38
31427564 2019
37
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. 38
30842207 2019
38
CTRP3 Alleviates Ox-LDL-Induced Inflammatory Response and Endothelial Dysfunction in Mouse Aortic Endothelial Cells by Activating the PI3K/Akt/eNOS Pathway. 38
30887395 2019
39
Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study. 38
31228771 2019
40
Acute myocardial infarction in a patient with active actinic rectitis bleeding: Between the sword and the wall. 38
31212360 2019
41
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. 38
31332544 2019
42
Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. 38
31345425 2019
43
National Trends, Gender, Management, and Outcomes of Patients Hospitalized for Myocarditis. 38
31060730 2019
44
Concomitant severe carotid and coronary artery diseases: a separate management or concomitant approach. 38
31269295 2019
45
Incremental Prognostic Value of Myocardial Blood Flow Quantified With Stress Dynamic Computed Tomography Perfusion Imaging. 38
30031698 2019
46
Study on Connective Tissue Growth Factor Expressed in Patients with ST-Segment Elevation Myocardial Infarction. 38
31371895 2019
47
Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. 38
31318428 2019
48
Subgroup Differences and Determinants of Patient-Reported Mental and Physical Health in Patients With Ischemic Heart Disease: Results From the DenHeart Study. 38
31135602 2019
49
H2FPEF Score as a Prognostic Value in HFpEF patients. 38
31271191 2019
50
Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease. 38
31362878 2019

Variations for Intermediate Coronary Syndrome

Expression for Intermediate Coronary Syndrome

Search GEO for disease gene expression data for Intermediate Coronary Syndrome.

Pathways for Intermediate Coronary Syndrome

Pathways related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13 VWF SERPINC1 SELP PLG PLAT P2RY12
2
Show member pathways
12.07 PLG PLAT IL6 CRP
3
Show member pathways
11.92 TNNT2 TNNI3 ITGA2B IL6 ACE
4 11.84 TNNT2 TNNI3 IL6
5
Show member pathways
11.8 PLG PLAT IL6
6 11.76 VWF P2RY12 ITGA2B
7
Show member pathways
11.76 VWF SERPINC1 PLG PLAT F3
8 11.49 TNNT2 TNNT1 TNNI3
9 11.29 VWF P2RY12 ITGA2B
10 11.16 VWF SERPINC1 PLG PLAT F3
11 10.94 SELP PLG PLAT IL6
12 10.91 PLG PLAT ACE
13 10.79 IL6 CRP
14 10.59 PLG PLAT

GO Terms for Intermediate Coronary Syndrome

Cellular components related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 VWF SERPINC1 PLG PLAT PIK3C2A MB
2 extracellular space GO:0005615 9.86 SERPINC1 SELP PLG PLAT IL6 F3
3 cell surface GO:0009986 9.8 PLG PLAT P2RY12 ITGA2B F3
4 external side of plasma membrane GO:0009897 9.78 SELP P2RY12 ITGA2B ACE
5 platelet alpha granule membrane GO:0031092 9.43 SELP ITGA2B
6 collagen-containing extracellular matrix GO:0062023 9.35 VWF SERPINC1 PLG PLAT F3
7 cardiac myofibril GO:0097512 9.32 TNNT2 TNNI3
8 cardiac Troponin complex GO:1990584 9.16 TNNT2 TNNI3
9 troponin complex GO:0005861 8.8 TNNT2 TNNT1 TNNI3
10 extracellular region GO:0005576 10.06 VWF SERPINC1 PLG PLAT IL6 F3

Biological processes related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 muscle contraction GO:0006936 9.72 TNNT2 TNNT1 TNNI3
2 platelet activation GO:0030168 9.71 VWF P2RY12 IL6
3 platelet degranulation GO:0002576 9.67 VWF SELP PLG ITGA2B
4 cardiac muscle contraction GO:0060048 9.61 TNNT2 TNNT1 TNNI3
5 muscle filament sliding GO:0030049 9.58 TNNT2 TNNT1 TNNI3
6 heart contraction GO:0060047 9.52 TNNI3 ACE
7 positive regulation of leukocyte migration GO:0002687 9.51 SELP ITGA2B
8 negative regulation of ATPase activity GO:0032780 9.49 TNNT2 TNNI3
9 negative regulation of lipid storage GO:0010888 9.48 IL6 CRP
10 neutrophil mediated immunity GO:0002446 9.46 IL6 ACE
11 skeletal muscle contraction GO:0003009 9.43 TNNT2 TNNT1 TNNI3
12 blood coagulation GO:0007596 9.43 VWF SERPINC1 PLG PLAT P2RY12 F3
13 regulation of muscle contraction GO:0006937 9.33 TNNT2 TNNT1 TNNI3
14 slow-twitch skeletal muscle fiber contraction GO:0031444 9.32 TNNT1 MB
15 hemostasis GO:0007599 9.02 VWF SERPINC1 PLG P2RY12 F3

Molecular functions related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.43 VWF SERPINC1 F3
2 tropomyosin binding GO:0005523 9.32 TNNT2 TNNT1
3 troponin T binding GO:0031014 9.16 TNNT1 TNNI3
4 troponin C binding GO:0030172 8.96 TNNT2 TNNI3
5 calcium-dependent ATPase activity GO:0030899 8.62 TNNT2 TNNT1

Sources for Intermediate Coronary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....